Previous close | 140.15 |
Open | 138.06 |
Bid | 0.00 x 0 |
Ask | 0.00 x 0 |
Day's range | 133.20 - 138.24 |
52-week range | 118.16 - 153.10 |
Volume | |
Avg. volume | 3,020 |
Market cap | 214.302B |
Beta (5Y monthly) | 0.19 |
PE ratio (TTM) | 36.19 |
EPS (TTM) | 3.82 |
Earnings date | N/A |
Forward dividend & yield | 2.86 (2.07%) |
Ex-dividend date | 22 Feb 2024 |
1y target est | N/A |
Dividends are one of the best benefits to being a shareholder, but finding a great dividend stock is no easy task. Does Astrazeneca (AZN) have what it takes? Let's find out.
WILMINGTON, Del., April 16, 2024--Updated exploratory results from the TOPAZ-1 Phase III trial showed AstraZeneca’s IMFINZI® (durvalumab) in combination with standard-of-care chemotherapy demonstrated a clinically meaningful long-term overall survival (OS) benefit at three years for patients with advanced biliary tract cancer (BTC).
The FDA approves AstraZeneca's (AZN) Fasenra as an add-on maintenance treatment for patients with severe asthma aged six to 11 years.